OSL · MEDI.OL
Medistim ASA
NOK 304.00-NOK 3.00 (-0.98%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
Loading market information…
OSL · CRNA.OL · NOK
Stock price, earnings
Quote as of Oct 30, 2026, 08:27 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
Circio Holding ASA’s quoted price sits in the upper half of its reported 52-week range, 32.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Circio Holding ASA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 304.00-NOK 3.00 (-0.98%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
NOK 25.80+NOK 0.40 (+1.57%)
Nordhealth AS’s quoted price sits in the lower half of its reported 52-week range, 32.81% below the high.
NOK 4.15-NOK 0.06 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
NOK 46.00-NOK 0.70 (-1.5%)
Photocure ASA’s quoted price sits in the lower half of its reported 52-week range, 42.36% below the high.
NOK 3.01-NOK 0.01 (-0.33%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 42.12% below the high.
NOK 7.80+NOK 0.04 (+0.52%)
IDEX Biometrics ASA’s quoted price sits in the upper half of its reported 52-week range, 39.06% below the high.
NOK 1.93-NOK 0.07 (-3.3%)
Nordic Nanovector ASA’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
NOK 1.17NOK 0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the lower half of its reported 52-week range, 92.54% below the high.
